Genvoya: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
[[Retroviral Integrase]] is produced by the HIV retrovirus, enabling [[HIV]] to integrate its genetic material into the [[DNA]] of the infected cell. This integration step effectively transforms the infected cell into a permanent carrier of the viral genome, allowing the virus to persist and proliferate nearly without limit.<ref>PMID:17107277</ref> HIV retroviral integrase forms "intasomes" when it <scene name='Elvitegravir/Full/1'>complexes with viral DNA</scene>. The integrase domains interact extensively with the viral DNA, <scene name='Elvitegravir/Tight/1'>binding the nucleotide chains</scene> precisely within an active site, in close proximity to the predicted target DNA into which the viral DNA will be inserted. Elvitegravir binds with great specificity to the HIV integrase active site. It orients itself in such a way as to displace the reactive viral DNA end from the active site almost completely. <scene name='Elvitegravir/Tightasdf/2'>Elvitegravir binds</scene> to residues Asp 128, Asp 185, & Glu 221 via strong interactions with magnesium ions and has extensive π-stacking interactions with the final two nucleotide rings on one viral DNA strand. This disruption prevents the viral DNA from interacting with the target DNA, preventing integration and HIV proliferation.<ref>doi: 10.1038/nature08784</ref><ref>PMID:21030679</ref> | [[Retroviral Integrase]] is produced by the HIV retrovirus, enabling [[HIV]] to integrate its genetic material into the [[DNA]] of the infected cell. This integration step effectively transforms the infected cell into a permanent carrier of the viral genome, allowing the virus to persist and proliferate nearly without limit.<ref>PMID:17107277</ref> HIV retroviral integrase forms "intasomes" when it <scene name='Elvitegravir/Full/1'>complexes with viral DNA</scene>. The integrase domains interact extensively with the viral DNA, <scene name='Elvitegravir/Tight/1'>binding the nucleotide chains</scene> precisely within an active site, in close proximity to the predicted target DNA into which the viral DNA will be inserted. Elvitegravir binds with great specificity to the HIV integrase active site. It orients itself in such a way as to displace the reactive viral DNA end from the active site almost completely. <scene name='Elvitegravir/Tightasdf/2'>Elvitegravir binds</scene> to residues Asp 128, Asp 185, & Glu 221 via strong interactions with magnesium ions and has extensive π-stacking interactions with the final two nucleotide rings on one viral DNA strand. This disruption prevents the viral DNA from interacting with the target DNA, preventing integration and HIV proliferation.<ref>doi: 10.1038/nature08784</ref><ref>PMID:21030679</ref> | ||
'''2) [[Cobicistat]]''' | '''2) [[Cobicistat]] - Cytochrome P450 inhibitor''' | ||
'''3) [[Emtricitabine]]''' | '''3) [[Emtricitabine]] - Reverse-transcriptase inhibitor''' | ||
'''4) [[Tenofovir disoproxil]] - Reverse-transcriptase inhibitor''' | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||